Although anti-CD20 monoclonal antibodies (mAbs) show promise for the treatment of chronic lymphocytic leukemia (CLL), the success of the anti-CD20 mAb rituximab in CLL treatment has been limited. Novel anti-CD20 mAbs with more potent cytotoxic activity have recently been engineered, but so far most have only been tested in vitro with natural killer (NK) cells from healthy donors. Because it is still unclear whether these optimized cytotoxic mAbs will improve NK-cell killing of tumor cells in CLL patients, we characterized the relevant phenotypic and functional features of NK cells from CLL patients in detail. Expression of inhibitory and activating NK-cell receptors and of Fc gamma receptor IIIA (FccRIIIA) is well preserved in CD16 þ CD56 dim cytotoxic NK cells from these patients, independently of disease progression. These cells are fully functional following cytokine stimulation. In addition, the FccRIIIA-optimized LFB-R603 anti-CD20 mAb mediates 100 times greater antibody-dependent cell-mediated cytotoxicity by NK cells from CLL patients and healthy donors than rituximab. Enhanced degranulation against autologous B-CLL cells is observed at lower concentrations of LFB-R603 than rituximab, regardless of CLL prognostic factors. These findings strongly justify further clinical development of anti-CD20 mAbs optimized for FccR engagement in CLL patients.
Introduction

Chronic lymphocytic leukemia (CLL) is an accumulation of CD5
þ /CD19 þ malignant monoclonal B lymphocytes with a highly variable clinical course. The introduction of therapeutic monoclonal antibodies (mAbs) has brought a remarkable change in treatment. The anti-CD52 alemtuzumab and anti-CD20 rituximab mAbs have been widely used in progressive disease. In contrast to alemtuzumab, rituximab is generally well tolerated with infrequent serious adverse effects that are generally well controlled. Although the combination of fludarabine and cyclophosphamide with rituximab is currently considered the 'gold standard' for the treatment of CLL, 1,2 it does not allow full-disease eradication and the disease can become resistant. The activity of rituximab is thought to be mediated through several mechanisms, including complement-dependent cytotoxicity, apoptosis, antibody-dependent cellular cytotoxicity (ADCC) and/or phagocytosis. 3 Strategies pursued to improve the efficacy of mAb therapy have included modifying the antibody structure to increase its affinity to the Fc gamma receptor IIIA (FcgRIIIA, CD16), an intermediate-affinity activating FcgR strongly expressed on natural killer (NK) cells. 4 Optimized mAbs, including AME-133, GA-101, veltuzumab (hA20) and ofatumumab (HuMax-CD20) [5] [6] [7] are at different stages of development. We previously described a novel chimeric anti-CD20 mAb, EMAB-6, characterized by low fucose content in its Fc region. EMAB-6 shows improved FcgRIIIA binding, resulting in enhanced ADCC, mediated particularly by macrophages 8 and NK cells. 9 The NK cells constitute a unique component of the innate immune system, able to recognize various targets without specific sensitization. The NK cells are heterogeneous and differ in their proliferative potential, homing characteristics, functional capabilities and in responses to a wide range of cytokines. Around 10% of NK cells in the peripheral blood are CD16 À CD56 bright . This immunoregulatory subset of NK cells produces a wide range of cytokines and chemokines, but its ability to kill target cells spontaneously is poor. In contrast, the rest (90%), corresponding to the CD16 þ CD56 dim cytotoxic NK-cell subset, produces relatively lower cytokine levels, but possesses an abundance of cytolytic granules and can spontaneously lyse susceptible target cells. 10 The complexity of the NK-cell compartment is attributable to the vast network of inhibitory or activating receptors that allow these cells to recognize target cells. The functional state of NK cells is, therefore, dictated by the balance between opposing signals. 11 Moreover, in the presence of mAbs, strong expression of FcgRIIIA allows CD16 þ CD56 dim NK cells to kill targets through ADCC, regardless of the presence of any inhibitory receptors. ADCC has been identified as a critical mechanism underlying the clinical efficacy of therapeutic antibodies, including rituximab. 12, 13 We focused our attention on NK cells in patients with CLL, because the size of this cell compartment is an independent factor predictive of the rate of disease progression in patients with newly diagnosed CLL.
14 Several studies have reported functional alterations in NK cells in these patients, including defective cytotoxic activity, which are particularly pronounced in advanced disease and that could be because of the accumulation of leukemic cells rather than to any intrinsic defect in the former. 15, 16 This hypothesis was suggested by the restoration of their functional activity after interferon (IFN)-a and/or interleukin (IL)-2 treatment. 17, 18 We conducted the first extensive characterization of the phenotypic and cytotoxic qualities of NK cells from CLL patients and compared them with those of healthy subjects. Our data reveal that NK cells from these patients have the major phenotypic features of competent NK cells and are able to function effectively. We also explored the preclinical activity of LFB-R603, a novel optimized anti-CD20 mAb, and show that at low doses this antibody promotes a significantly higher percentage of NK cell-mediated degranulation against autologous CLL cells than rituximab.
Patients and methods
Patients and control donors
Fresh blood samples were collected from 57 CLL patients followed at Pitié-Salpêtrière Hospital (Paris, France). All patients met the morphological and phenotypic criteria for typical CLL (Matutes score X4). 19 They had not been treated previously or had not received any treatment during the 6 months before the study. None of these patients had received rituximab or alemtuzumab. Binet stage A patients were considered to have an unfavorable prognosis if they met any two of the following four criteria: (1) Presence of unmutated Immunoglobulin heavy variable chain sequences with a V H gene sequence p2% of sequence alterations compared with the published germline sequence; (2) High expression of surface CD38 (420%); (3) High expression of cytoplasmic ZAP-70 (420%); and (4) Clonal cytogenetic abnormalities, including deletion of chromosomes 17p or 11q or trisomy of chromosome 12, revealed by fluorescent-labeled DNA probes used in interphase fluorescence in situ hybridization (probes 17p13.1, ATM 11q23 and CEP12, respectively). 20 Patients with del (13q) (probe 13q14), have an excellent prognosis if they do not have additional defects. Patients with 17pÀ were considered to have an unfavorable prognosis even if all their other criteria were favorable. All other Binet stage A patients were considered to have a favorable prognosis. The control group comprised sex-and age-matched outpatient volunteers from the rheumatology (n ¼ 29), who had consulted for noninflammatory arthritic pathology such as osteoarthritis, or gerontology (n ¼ 38) departments at Pitié-Salpêtrière or Charles-Foix Hospital, respectively. Our study applied restrictive health selection criteria, including no infectious or malignant diseases 6 months before the study and without acute illness at the time of sampling. None of the control patients had an autoimmune disease. All case and control patients provided a written, informed consent before participation. The local ethics committee approved the study.
Flow cytometry and absolute B cell, T cell, and NK cell counts À CD56 dim NK cells was quantified using QuantiBRITE standard beads (BD Biosciences), as recommended by the manufacturer. For intracellular IFN-g staining, peripheral blood mononuclear cells (PBMC) were incubated overnight in the presence of IL-12 (10 ng/ml) and IL-18 (100 ng/ml) (R&D Systems). Cells were fixed and permeabilized with a cytofix/ cytoperm kit (BD Biosciences), and stained with IFN-g mAb (B27; BD Biosciences), as described. 21 Direct cytolytic activity of NK cells NK cell-enriched PBMC (8 CLL patients and 5 controls) were tested for direct cytotoxicity. NK cell-enriched PBMC fractions were obtained after negative depletion (anti-CD19-coated beads) followed by positive selection (anti-CD56-coated beads) (Miltenyi Biotec, Bergish Gladbach, Germany). Similar proportions of NK cells were detected in NK cell-enriched PBMC fractions from CLL patients (38 ± 11%) and controls (42 ± 10%). The B cells accounted for 30±20% of the residual cells for CLL patients and 1±2% for controls, whereas the proportions for T cells were 31 ± 17% and 55 ± 11%, respectively. Direct cytotoxicity was assessed after IL-2 stimulation (proleukin-2, 1000 IU/ml) for 72 h, with a standard 4-h 51 Cr-release assay against the human leukocyte antigen (HLA) class I-deficient human K562 cell line. 21 Anti-CD20 LFB-R603 antibody LFB-R603 is a chimeric mAb directed against CD20 with a glycosylation profile that allows increased binding to CD16. This mAb has been granted an orphan-drug status in Europe and in the USA for CLL treatment (http://www.lfb.fr/en/home.html). A previous generation of this antibody, named EMAB-6, sharing the same specificity and a similar glycosylation pattern, was described in de Romeuf et al.
9
Purification of NK cells and ADCC assay
Purified NK cells (498% CD3
À CD56 þ cells) from 7 CLL patients and 6 controls were obtained from peripheral blood after centrifugation on a Ficoll/Hypaque gradient, followed by negative selection with anti-CD19-coated beads (Miltenyi Biotec) and cytofluorometric selection of CD3 À CD56 þ NK cells on a FACSVantage (BD Biosciences). ADCC assays were performed with purified NK cells and 51 Cr-labeled Raji cells at an effector-target (E:T) ratio of 10:1. Experiments were performed in the presence of LFB-R603 (LFB) or rituximab (Roche Ltd, Basel, Switzerland) at concentrations ranging from 0.1 to 10 000 ng/ml.
Degranulation of NK cells
The degranulation marker CD107a was detected on freshly isolated PBMC from both CLL patients and controls by co-staining for NK markers (CD3 À CD56 þ NK cells). Cells were incubated with anti-CD107a mAb (H4A3; BD Biosciences), with 10 or 1000 ng/ml of either anti-CD20 rituximab (Roche) or LFB-R603 (LFB, Les Ulis, France), as described. 21 
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Statistical analysis
Statistical analyses were performed with Prism 4 software (GraphPad Software, San Diego, CA, USA). Intergroup comparisons were assessed with the Mann-Whitney U-test or Wilcoxon rank-sum test. P-values less than 0.05 were considered statistically significant; *Po0.05, **Po0.01, ***Po0.001. Table 1 and Supplementary Table 1 show the main clinical and biological prognostic characteristics of CLL patients included in this study. Because the potential benefit of early treatment for unfavorable prognosis Binet stage A patients is a key therapeutic question, patients were divided into two groups according to their biological prognostic factors. Binet stage A CLL patients with an unfavorable prognosis were classified with Binet stage B/C patients (group 2, n ¼ 23) and compared with stage A patients with a favorable prognosis (group 1, n ¼ 34). There was no significant difference in the sex ratio or median age between groups 1 and 2.
Results
CLL patients
Distribution of lymphocyte subsets in CLL patients
Flow cytometry was used to measure CD19 
Phenotypic analysis of NK receptors in CLL patients
The phenotypic properties of the CD3 À CD56 dim cytotoxic NKcell subset were investigated further by gating out CD3 À CD56 bright NK cells. CD56 dim NK cells from CLL patients, irrespective of their prognostic status, were indistinguishable from those of controls in terms of cell-surface expression of the major NK receptors studied, including c-lectin receptors (NKG2A, NKG2C and NKG2D), natural cytotoxicity receptors (NKp30, NKp44 and NKp46) and other NK-cell markers such as NKp80, ILT-2, LAIR-1 and 2B4 ( Figure 2a , upper panels; data not shown). Similar phenotypic results were observed according to the Binet stages (A vs B/C) (data not shown). This phenotype was then studied longitudinally, over a 1-year period, comparing the initial samples with samples taken 2, 4, 6 and/or 12 months later. A remarkable phenotypic stability was observed for each NK receptor studied. Figure 2a (lower panels) shows representative CLL patients from each of the groups (patients 1 and 2, group 1; patient 3, group 2; patient 4, group 1 (at first evaluation) and group 2 (at 12 months)). These results were confirmed with three other patients (data not shown). In addition, patient 4's NK receptor repertoire remained stable during disease progression between stages A (group 1) and C (group 2) after 1 year. The only difference observed in the KIR was a weak, but significant decrease in expression of KIR2DL1/DS1, which recognizes group-2 HLA-Cw alleles, in CLL patients with an unfavorable prognosis compared with controls (P ¼ 0.0370). Binet B/C patients presented a nonsignificant decrease compared with controls (data not shown). No differences between groups were observed for the other KIRs tested, including KIR2DL2-3/DS2, which binds group-1 HLA Cw ligands, and KIR3DL1/DS1, which recognizes HLA-Bw4 (Figure 2b) .
The expression pattern of the early activation marker CD69 on CD3 À CD56 þ NK cells was also investigated. As shown in Figure 2c , CD69 expression in CD3 À CD56 dim NK cells was slightly, but significantly lower in CLL patients than in controls (group 1 vs controls: P ¼ 0.0228, and group 2 vs controls: P ¼ 0.0044), even if a certain degree of overlap of CD69 expression in CD3 À CD56 dim NK cells was observed between both groups of CLL patients and controls. Similarly, CD69 expression decreased significantly in CD3 À CD56 bright immunoregulatory NK cells from group 1 patients compared with controls (P ¼ 0.0037). Furthermore, HLA-DR expression, a late cell-activation marker, remained close to background levels in all control and CLL subjects, in all NK-cell subsets (data not shown). Similar results were obtained according to Binet stages (data not shown).
Functional analysis of NK cells in CLL patients
The functional capacities of the NK-cell compartment of CLL patients were investigated further. As shown in Figure 3a , intracellular IFN-g in CD3 À CD56 dim NK cells from CLL patients NK cells and optimized anti-CD20 in CLL M Le Garff-Tavernier et al (groups 1 and 2) treated with IL-12 and IL-18 was expressed at a similar level to that in NK cells from controls. Similar results were observed in the CD3 À CD56 bright NK-cell subset even if IFN-g expression increased slightly in CLL patients (group 1 and group 2) compared with controls (P ¼ 0.0359 and P ¼ 0.0176, respectively) (Figure 3b) . The direct cytotoxicity of NK cells was then evaluated after IL-2 activation by their capacity to lyse HLA class-I negative K562 sensitive-target cells and Figure 3c shows that the cytotoxicity of NK cell-enriched PBMC from CLL patients was similar to that in controls.
ADCC potency of NK cells from CLL patients is related to the concentration of rituximab and LFB-R603 NK-cell cytolysis can also be induced indirectly through Fc receptors, by antibodies mediating ADCC. ADCC assays with purified NK cells against Raji target cells, in the presence of serial concentrations of rituximab or LFB-R603, produced similar ADCC curves in controls and CLL patients with both anti-CD20 mAbs, including an exponential phase followed by a plateau (Figure 4a ). The effect in CLL patients was similar irrespective of their prognostic status. However, the potency was dose-dependent for both rituximab and LFB-R603, and the maximum ADCC was detected at 1 ng/ml of LFB-R603, but at 100 ng/ml of rituximab. This indicates that the potency of LFB-R603 is superior to that of rituximab (Figure 4a ). At 1 ng/ml, the median ADCC value with LFB-R603 was 62.5% for controls and 65.1% for CLL patients, whereas at a similar dose of rituximab, the ADCC was significantly lower (P ¼ 0.03) at 7.3 and 8.5%, respectively (Figure 4b, upper panel) . In contrast, the ADCC with both anti-CD20 mAbs was similar at 100 ng/ml in CLL patients and controls (Figure 4b, lower panel) . As shown in Figure 4c , in CLL patients, EC50 values were 10.5 ng/ml for rituximab and 0.13 ng/ml for LFB-R603, which indicates that the ADCC activity of the latter was 81 times higher than that of rituximab. In the control subjects, EC50 values were 16.2 ng/ml for rituximab and 0.16 ng/ml for LFB-R603, with LFB-R603 ADCC activity 101 times higher than that of rituximab. Taken together, these results confirm the strong ADCC capacity of NK cells from CLL patients and suggest that, at least ex vivo, LFB-R603 is more potent than rituximab at low concentrations.
The degranulation capacities of NK cells from CLL patients in the presence of their autologous B-CLL cells provide additional support for these data because ADCC is influenced not only by binding of NK cells to their target but also and mainly by their ability to degranulate. This ex vivo model evaluated the 
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M Le Garff-Tavernier et al proportion of CD107a þ NK cells in whole PBMC from CLL patients and controls. As shown in Figure 5a , analysis of degranulation in the presence of autologous target cells confirmed the greater potency of LFB-R603 compared with rituximab: although NK-cell degranulation was not observed in samples from any of the 21 CLL patients at low concentrations of rituximab (10 ng/ml), the median values of degranulation with the same concentration of LFB-R603 were 16.3% in group 1 and 15.2% in group 2 (Figure 5a ). Similar results were obtained using the Binet stages (data not shown). At a higher concentration (1000 ng/ml), NK-cell degranulation remained significantly higher with LFB-R603 than with rituximab (group 1, P ¼ 0.0005 and group 2, P ¼ 0.0078) (Figure 5b ). According to Binet stages, this difference remained significant in the A patient group but not in the B/C patient group, probably because of the low number of patients in this latter group (data not shown). Finally, we could not exclude that CLL cells inhibited NK-cell function.
To test this hypothesis, we added Raji cells into the CD107 degranulation assay performed with PBMC from CLL patients or healthy controls. As shown in the Supplementary Figure 1 , in the presence of Raji cells, the CD107 level in NK cells was similar in CLL patients and healthy controls, suggesting an absence of effect of CLL cells on NK degranulation. Together, these data demonstrate that in the presence of autologous B-CLL target cells, the proportion of degranulating NK cells was considerably higher with LFB-R603 than with rituximab.
Discussion
This report describes the first extensive phenotypic and functional study of CD16 þ CD56 dim NK cells in CLL patients and age-matched controls. CLL patients were found to have a significantly higher number of NK cells, as previously described, 22 but expression of both inhibitory and activating NK-cell receptors was well preserved. In addition, this NK-cell repertoire remained remarkably stable despite disease progression. Intriguingly, only a slight decrease in KIR2DL1/DS1 expression was noted in patients with an unfavorable prognosis, whereas the frequency of HLA-Cw*06, a KIR2DL1 ligand, was significantly higher in CLL cohorts than in controls. 23, 24 The phenotypic features of these CD16 þ CD56 dim NK cells cannot explain the lack of antitumor activity or disease control. This may suggest a failure to express some NK ligands on B-CLL cells, such as MICA and ULBPs, as previously reported. 25 In contrast, the major phenotypic alterations in NK cells observed in acute leukemia, including the downregulation of natural cytotoxicity receptors, 26, 27 suggest that chronic and acute leukemia use 
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þ CD56 dim NK cells from CLL patients; this deficit could explain the previously reported reduction in NK cytotoxic activity in the absence of exogenous stimulation. 15, 28 This relative NK-cell anergy could be due to the ability of CLL cells and their microenvironment to produce cytokines, such as IL-10, which suppress the proliferation of antigen-specific Th1 cells and downregulate co-stimulatory molecules on antigen-presenting cells. [29] [30] [31] Importantly, NK-cell function was perfectly recovered following activation. This included the ability to produce large amounts of IFN-g after IL-12 and IL-18 activation, and effective cytolysis against major histocompatibility complex % NK ADCC class-I-defective K562 target cells after IL-2 activation. Similar capacities were observed in all patients, regardless of their prognostic factors in agreement with previous reports. 17, 18 Altogether, these results contribute to our knowledge on NK-cell nature and function in CLL.
Our results demonstrate the efficacy of NK cells from CLL patients, including patients with an unfavorable prognosis, at killing tumor Raji cells and degranulating against autologous B-CLL cells. Consequently, these data strongly support the use of anti-CD20 mAbs optimized for FcgR engagement to induce efficient ADCC. Surprisingly, very few studies have evaluated anti-CD20 mAb-mediated ADCC in CLL, 9, 32 with most anti-CD20 ADCC studies using non-Hodgkin's lymphoma cell lines. Only two studies have investigated the ability of NK cells to mediate ADCC against primary CLL cells in the presence of anti-CD20 mAbs. 9, 32 Weitzman et al. 32 showed that rituximab and veltuzumab, another anti-CD20 mAb optimized for enhanced complement-dependent cytotoxicity, resulted in similar levels of ADCC in the presence of primary CLL cells and NK cell lines. Recently, we have shown that EMAB-6, an anti-CD20 optimized for FcgRIIIA engagement, induced greater ADCC against CLL cells than rituximab, in the presence of NK cells from healthy donors. 9 Of note, we focused our attention on NK cell-mediated ADCC. However, we cannot exclude a synergistic effect of macrophages and neutrophils with NK cells in this mechanism. 8, 33 Other studies have focused on the cytotoxic activity of anti-CD20 mAbs against non-Hodgkin's lymphoma cells. With optimized GA-101 anti-CD20 mAb, the potency of ADCC against CD20-expressing non-Hodgkin's lymphoma cells ranges from 5 to 100 times greater than with rituximab. 34 Similarly, AME-D, another optimized anti-CD20 mAb, produces greater ADCC at lower mAb concentrations than rituximab against an non-Hodgkin's lymphoma cell line. 35 In the presence of NK cells from CLL patients, similar dose-response relationships were found for the induction of ADCC by the optimized anti-CD20 LFB-R603 mAb and rituximab, except that LFB-R603 could kill the same number of Raji cells at 1/100 the concentration of rituximab. ADCC did not increase with concentrations higher than 100 ng/ml for rituximab or 1 ng/ml for LFB-R603. Of note, LFB-R603 induces strong ADCC at a low concentration (1 ng/ml), regardless of the prognostic factors.
Importantly, a robust increase in NK-cell degranulation against autologous CLL cells was observed in the presence of LFB-R603, in contrast to the results with rituximab. Together, these data indicate that the potency of ADCC with these two anti-CD20 mAbs differs considerably and that the anti-CD20 LFB-R603 mAb triggers better effector functions to clear CLL cells, which may be therapeutically beneficial. Intriguingly, considerable interindividual variation in degranulation efficacy was also observed, regardless of the patients' prognosis. Previous studies have shown that the FcgRIIIA polymorphism is associated with differential affinity and binding to human IgG1 mAbs. However, in CLL, the FcgR polymorphism did not predict responses to low-fucosylated mAbs, 32, 36, 37 suggesting that this polymorphism does not explain the variability in degranulation responses. Instead, NK-cell degranulation might be affected by the effector/target ratio, in agreement with Fischer et al. 38 Finally, the individual variability might be also attributed to intrinsic resistance of CLL cells to degranulation as observed in 1/21 patients. Moreover, we noted a defect in NK-cell degranulation in two patients who had received rituximab before sampling (data not shown). Accordingly, functional characterization of NK cells against autologous B-CLL targets from each patient might be useful for predicting the quality of the response to anti-CD20 treatment in relationship to clinical treatment history.
In CLL, the introduction of anti-CD20 mAbs has brought about a remarkable change in treatment strategy, but limitations in their therapeutic use have also been noted. Rituximab is not widely used alone in CLL because of its low-response rate and the short-response duration. Furthermore, increased doses of rituximab, from 500 to 2250 mg/m 2 , are associated with significant toxicity without any enhancement of clinical benefits. 39 On the basis of these success and limitations, different types of second-generation mAbs have been engineered. Ofatumumab (HuMax) and veltuzumab are designed to improve complement-dependent cytotoxicity, whereas GA-101 and LFB-R603, for example, are intended to increase the affinity of the mAb Fc region for FcgRIIIA, by amino-acid substitutions or modification of the carbohydrate structure of the mAb, or both. Lower doses of these antibodies must be sufficient to produce ADCC levels similar to or higher than those achieved with rituximab, as demonstrated in this study. Clinical trials with these antibodies may reveal that they have enhanced activity compared with rituximab, but without its side effects. Thus, an interim analysis in an international phase I trial of ofatumumab, used as single agent at a dose of 2000 mg in refractory CLL patients, reported a good safety profile and a high overall response rate in heavily pretreated patients. 40 A multicenter phase I study of GA-101, used as single agent at escalating doses of 400-2000 mg, showed good responses with two cases of complete remission at intermediate doses (800/1200 mg), a tumor-burden decrease and good tolerance in 11/13 evaluable CLL patients. 41 Finally, an ongoing phase I study is testing LFB-R603 at doses escalating from 75 to 1650 mg/m 2 . In summary, our findings clearly demonstrate that peripheral NK cells from CLL patients are functional in terms of degranulation and ADCC, although a certain degree of variability is observed. They support the idea that a functional characterization of NK cells from each CLL patient could be useful in predicting the outcome of clinical treatment with mAbs. Our data also show that LFB-R603 activity is more promising than that of rituximab. The potency of LFB-R603 at low doses may have an important impact in patients with severe disease or in those who are resistant to chemotherapy.
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